株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

心血管・代謝性疾患向け幹細胞療法の世界市場:2019年~2030年

Global Stem Cell Therapy Market: Focus on Cardiovascular and Metabolic Disorders, 2019-2030

発行 ROOTS ANALYSIS 商品コード 808189
出版日 ページ情報 英文 300 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.90円で換算しております。
Back to Top
心血管・代謝性疾患向け幹細胞療法の世界市場:2019年~2030年 Global Stem Cell Therapy Market: Focus on Cardiovascular and Metabolic Disorders, 2019-2030
出版日: 2019年03月31日 ページ情報: 英文 300 Pages
概要

当レポートでは、心血管・代謝性疾患向け幹細胞療法について調査分析し、現在の市場情勢、アンメットニーズ、注目分野、パートナーシップ、投資、出版分析、承認済み/後期開発品などについて、体系的な情報を提供しています。

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 市場情勢

  • 概要
  • 心血管・代謝性疾患向け幹細胞療法:上市薬、開発パイプライン
  • 心血管・代謝性疾患向け幹細胞療法:開発企業情勢
  • 心血管・代謝性疾患向け幹細胞療法:追加情報
  • 心血管・代謝性疾患向け幹細胞療法:学術貢献
  • 脳卒中向け幹細胞療法

第5章 アンメットニーズ分析

  • 概要
  • 心血管・代謝性疾患向け幹細胞療法のアンメットニーズ分析
    • 患者ブログ
    • 既刊文献
    • ソーシャルメディアプラットフォーム
    • 専門家の見解
    • サマリー

第6章 主な治療分野

  • 概要
  • 心血管疾患
    • 心不全
    • 心筋梗塞
    • 重症肢虚血
  • 代謝性疾患
    • 糖尿病

第7章 企業の競合分析

  • 概要
  • 調査手法
  • 前提条件と主要パラメーター
  • 競合分析

第8章 パートナーシップ・提携

  • 概要
  • パートナーシップモデル
  • 心血管・代謝性疾患向け幹細胞療法:パートナーシップ・提携のリスト

第9章 資金・投資分析

  • 概要
  • 資金のタイプ
  • 心血管・代謝性疾患向け幹細胞療法:資金・投資分析
  • 結論

第10章 出版 (公表) 分析

  • 概要
  • 調査手法
  • 心血管・代謝性疾患向け幹細胞療法:出版物のリスト

第11章 心血管疾患向け幹細胞療法:療法プロファイル

第12章 代謝性疾患向け幹細胞療法:療法プロファイル

第13章 市場予測

  • 概要
  • 予測手法と主要パラメーター
  • 心血管・代謝性疾患向け幹細胞療法:総合市場
  • 心血管疾患向け幹細胞療法:総合市場
  • 代謝性疾患向け幹細胞療法:総合市場

第14章 結論

第15章 エグゼクティブ考察

第16章 付録1:図表データ

第17章 付録2:企業・組織のリスト

目次
Product Code: RA100129

Example Highlights:

In order to achieve a competitive edge, therapy developers are increasingly focusing on conducting clinical trials ac ross different geographies for multiple indications.

Overview:

Cardiovascular disorders and metabolic disorders are considered to be amongst the leading causes of death worldwide. In fact, approximately one-third of the annual number of deaths across the globe are attributed to cardiovascular disorders. In the US, the annual economic burden associated with these disorders is estimated to be over USD 500 billion. According to a study conducted by RTI International for the American Heart Association, the prevalence of cardiovascular diseases is expected to rise to 45% of the overall US population, while affiliated costs are expected to be over USD 1 trillion by 2035. Despite considerable advances in healthcare, most of the currently available treatment options for cardiovascular disorders focus on palliative care and cannot actually repair damaged cardiac tissue. Although heart transplant is a viable option to treat complex cardiovascular conditions, the waiting time associated with this alternative is excruciatingly long.

Likewise, a significant proportion of the global population suffers from diabetes or some form of metabolism related clinical condition. As per IDF Diabetes Atlas, the treatment of diabetes and related complications incurred USD 727 billion in global healthcare expenditure in 2017. In 2017, it was estimated that 425 million individuals, between the ages 20 years to 79 years, were living with diabetes across the globe, and this number is expected to increase substantially in the foreseen future. Similar to cardiovascular diseases, most of the current treatment options for metabolic disorders are indicated for only controlling / managing disease related symptoms.

Advances in cell biology and regenerative medicine have led to the development of stem cell therapies that can potentially address several unmet needs and potentially offer a cure for various cardiovascular and metabolic disorders. The field of regenerative medicine has evolved substantially in the recent past; the first stem cell therapy, called Cellgram®-AMI (2011), was approved by the Ministry of Foods and Drug Safety of Korea, for the treatment of acute myocardial infarction. Presently, two other stem cell-based treatment options, namely HeartSheet (heart failure, 2015) and Stempeucel (critical limb ischemia, 2017), are commercially available for cardiovascular disorders. For metabolic disorders, most stem cell therapy candidates are still under development. However, there is one approved product, called Strimvelis for ADA-SCID (2016). Several stakeholders are engaged in efforts to advance the development of regenerative therapies for both cardiovascular and metabolic disorders. In fact, venture capital (VC) firms and government bodies are actively funding several such ongoing research initiatives.

Scope of the Report:

The “Stem Cell Therapies for Cardiovascular & Metabolic Disorders, 2019-2030” report features an extensive study of the current market landscape and the future potential of stem cell therapies in treating the aforementioned clinical conditions. The study includes all stem cell therapies that are being developed for the treatment of cardiovascular and metabolic disorders. In addition, we have provided a list of stem cell therapies being developed for stroke, a condition associated with vasculature in the brain. Amongst other elements, the report features the following:

  • A detailed assessment of the current market landscape of stem cell therapies with respect to target therapeutic area (cardiovascular and metabolic), phase of development (approved, phase III, phase II, phase I and preclinical / discovery), target disease indications (Cardiovascular: heart failure, myocardial infarction, critical limb ischemia, angina, peripheral arterial / vascular diseases, myocardial ischemia, myocardial fibrosis, cardiomyopathy and coronary microvascular dysfunction; Metabolic: diabetes, mucopolysaccharidosis type III, ADA-SCID, obesity, mitochondrial disorders and metachromatic leukodystrophy), source of cells (autologous and allogenic), type of stem cells (adult multipotent, adult pluripotent, embryonic multipotent, embryonic pluripotent and others), stem cell lineage (bone marrow, peripheral blood, adipose tissue, cardiosphere, muscle, Wharton's jelly, umbilical cord, placenta, dental pulp, cord blood and pancreas), and route of administration (intramyocardial, intramuscular, intravenous, intracoronary, subcutaneous implantation and surgical implantation).
  • An analysis highlighting the key unmet needs across cardiovascular and metabolic disorders, featuring insights generated from social media posts, recent scientific publications, patient blogs and the views of contemporary key opinion leaders as expressed on online platforms.
  • An overview of the focus areas of therapy developers, including an assessment of the existing opportunity for stem cell therapies across diverse therapeutic indications.
  • An insightful company competitiveness analysis featuring a three-dimensional bubble representation, highlighting the key players in this domain on the basis of the strength of their respective product portfolios, taking into consideration the number of therapies under development, phase of development of these therapies, number of disease indications being targeted and geographical distribution of affiliated clinical trials.
  • An analysis of the partnerships that have been established in the domain in the period 2012-2018, covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and / or commercialization agreements, manufacturing agreements, clinical trial agreements, process development agreements, and other relevant deals.
  • An analysis of the investments made at various stages of development in companies that are focused in this area, including seed financing, venture capital financing, capital raised from IPOs / secondary offerings, debt financing and grants.
  • An analysis of contemporary peer-reviewed scientific research articles published during the period 2013-2018, highlighting the key focus areas of the ongoing research activity, in terms of therapeutic area, target disease indication, and source of cells.
  • Comprehensive profiles of approved and late stage clinical products; each profile features an overview of the therapy, its mechanism of action, history of development, current development status, key clinical trial results, details on recommended dose, price and manufacturing process (wherever available).
  • One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2019-2030. The report includes information on (potential) sales-based revenues generated by stem cell therapies that are currently marketed or are in late stages of development for the treatment of cardiovascular and metabolic disorders. Additionally, it presents details on the likely distribution of the current and forecasted opportunity across [A] target therapeutic areas (cardiovascular and metabolic), [B] target disease indications (myocardial ischemia, heart failure, critical limb ischemia, diabetes, ADA-SCID, metachromatic leukodystrophy, and other cardiovascular and metabolic disorders ), [C] type of stem cells (adult multipotent, adult pluripotent and embryonic multipotent), [D] source of cells (autologous and allogenic), [E] stem cell lineage (bone marrow, peripheral blood and others), [F] route of administration (intramyocardial, intracoronary, intramuscular, intravenous and surgical implantation) and [G] key geographical regions (North America, Europe and Asia Pacific). To account for the uncertainties associated with the development of novel therapy products and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Michel Revel (Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Business Development Manager, Kadimastem)
  • Xuejun H Parsons (Chief Executive Officer, Xcelthera)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents:

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the current scenario and the likely evolution of the stem cell therapies market for cardiovascular and metabolic disorders in the short to mid-term and long term.

Chapter 3 features a brief introduction to the basic concepts related to stem cell-based therapies and the intricacies of their development and administration. In addition, it includes information on the various types of stem cell therapies (based on the source, potency and lineage of stem cells), modes of delivery and the diseases targeted by such therapies. Further, it provides details on cardiovascular and metabolic disorders, and the key indications that are being considered for treatment using stem cell therapies. Additionally, it highlights the challenges associated with stem cell therapies and provides brief insights on the anticipated future of such therapies, focusing on the treatment of cardiovascular and metabolic disorders.

Chapter 4 includes information on over 60 therapies that are currently approved / under development by industry players for the treatment of cardiovascular or metabolic disorders. It features a comprehensive analysis of pipeline therapies, highlighting the target therapeutic area (cardiovascular and metabolic), phase of development (approved, phase III, phase II, phase I and preclinical / discovery), target disease indication (Cardiovascular: heart failure, myocardial infarction, critical limb ischemia, angina, peripheral arterial / vascular diseases, myocardial ischemia, myocardial fibrosis, cardiomyopathy and coronary microvascular dysfunction; Metabolic: diabetes, mucopolysaccharidosis type III, ADA-SCID, obesity, mitochondrial disorders and metachromatic leukodystrophy), source of cells (autologous and allogenic), type of stem cells (adult multipotent, adult pluripotent, embryonic multipotent, embryonic pluripotent and others), stem cell lineage (bone marrow, peripheral blood, adipose tissue, cardiosphere, muscle, Wharton's jelly, umbilical cord, placenta, dental pulp, cord blood and pancreas), and route of administration (intramyocardial, intramuscular, intravenous, intracoronary, subcutaneous implantation and surgical implantation). Additionally, the chapter features information on over 40 therapies that are currently being developed by academic players. It also lists over 15 therapies that are being developed for the treatment of stroke.

Chapter 5 highlights the key unmet needs associated with stem cell therapies that are currently available / being developed for cardiovascular and metabolic disorders. The chapter provides detailed analysis of the various challenges and areas of concern, which were identified from views expressed by patients / experts across different platforms, such as social media posts, recent scientific publications, patient blogs, and the inputs of key opinion leaders. The chapter presents insightful word clouds, summarizing the opinions expressed across various public online portals.

Chapter 6 highlights the key target indications (myocardial infarction, heart failure, critical limb ischemia and diabetes) for which more than 7 stem cell therapies are currently under development. For each of these diseases, the chapter provides details on epidemiology, available treatment options, and the current market landscape of stem cell therapies (with respect to type of stem cell therapy, companies involved and phase of development).

Chapter 7 presents a three-dimensional bubble analysis highlighting the key companies (focused on cardiovascular and metabolic disorders) on the basis of the strength of their respective product portfolios, which takes into account the number of therapies under development, phase of development of candidate therapies, number of disease indications being targeted and geographical distribution of affiliated clinical trials.

Chapter 8 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market. We have also discussed the different partnership models (including R&D collaborations, licensing agreements, mergers and acquisitions, product development and / or commercialization agreements, manufacturing agreements, clinical trial agreement, process development agreement and other deals), and the most common forms of deals / agreements that have been established from 2012 to 2018.

Chapter 9 presents details on various investments and grants received by companies that are engaged in this domain. It includes a detailed analysis of the funding instances that have taken place during the period between 2012-2018, highlighting the growing interest of the venture capital community and other strategic investors within this market.

Chapter 10 provides a publication analysis, highlighting the recent trends in published literature related to stem cell therapies for cardiovascular and metabolic disorders. The chapter highlights the key focus areas of the ongoing research activity, in terms of type of therapeutic area, target disease indication, and source of cells.

Chapter 11 contains detailed profiles of drugs that are recently approved or are in advanced stages of clinical development (phase III) for cardiovascular disorders. Each profile features an overview of the therapy, its mechanism of action, history of development, current development status, key clinical trial results, details on administered dose, price and manufacturing process (wherever available).

Chapter 12 contains detailed profiles of drugs that are recently approved or are in advanced stages of clinical development (phase II or above) for metabolic disorders. Each profile features an overview of the therapy, its mechanism of action, history of development, current development status, key clinical trial results, details on administered dose, price and manufacturing process (wherever available).

Chapter 13 presents a comprehensive market forecast analysis, highlighting the future potential of the market till the year 2030. It provides the market estimations for therapies that are either already approved or are in the late phases of clinical development (phase III), taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price. The chapter also presents a detailed segmentation of the opportunity on the basis of [A] target therapeutic area (cardiovascular and metabolic), [B] target disease indications (myocardial ischemia, heart failure, critical limb ischemia, diabetes, ADA-SCID, metachromatic leukodystrophy, and other cardiovascular and metabolic disorders), [C] type of stem cells (adult multipotent, adult pluripotent and embryonic multipotent), [D] source of cells (autologous and allogenic), [E] stem cell lineage (bone marrow, peripheral blood and others), [F] route of administration (intramyocardial, intracoronary, intramuscular, intravenous and surgical implantation) and [G] key geographical regions (North America, Europe and Asia Pacific).

Chapter 14 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 15 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of interviews held with Michel Revel (Chief Scientist, Kadimastem), Galit Mazooz-Perlmuter (Business Development Manager, Kadimastem), and Xuejun H Parsons (Chief Executive Officer, Xcelthera).

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 17 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3 Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Stem Cell Therapy
    • 3.2.1. Classification of Stem Cell Therapies by Type of Cells
      • 3.2.1.1. Embryonic Stem Cells
      • 3.2.1.2. Adult Stem Cells
      • 3.2.1.3. Induced Pluripotent Stem Cells
      • 3.2.1.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
    • 3.2.2. Applications of Stem Cell Therapy
  • 3.3. Overview of Cardiovascular Disorders
    • 3.3.1. Key Indications being Investigated for Treatment with Stem Cells
  • 3.4. Overview of Metabolic Disorders
    • 3.4.1. Key Indications being Investigated for Treatment with Stem Cells
  • 3.5. Administration of Stem Cell Therapies
  • 3.6. Challenges Associated with Developing Stem Cell Therapies
  • 3.7. Future Perspectives

4. MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Marketed and Development Pipeline (Industry Players)
    • 4.2.1. Analysis by Target Therapeutic Area
    • 4.2.2. Analysis by Phase of Development
    • 4.2.3. Analysis by Source of Stem Cells
    • 4.2.4. Analysis by Type of Stem Cells
    • 4.2.5. Analysis by Stem Cell Lineage
    • 4.2.6. Analysis by Route of Administration
    • 4.2.7. Analysis by Target Indication
      • 4.2.7.1. Cardiovascular Disorders
      • 4.2.7.2. Metabolic Disorders
    • 4.2.8. Key Developers
    • 4.2.9. Heptagon Representation: Analysis by Target Indication and Phase of Development of Stem Cell Therapies
    • 4.2.10. Grid Analysis: Target Indications, Phase of Development and Source of Stem Cells
  • 4.3. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Developer Landscape
    • 4.3.1. Distribution by Focus Area
    • 4.3.2. Distribution by Year of Establishment
    • 4.3.3. Distribution by Size of Developer
    • 4.3.4. Distribution by Geographical Location
    • 4.3.5. Mapping Regional Activity
    • 4.3.6. Logo Landscape: Analysis by Size and Target Therapeutic Area
  • 4.4. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Additional Information
    • 4.4.1. Information on Dosage
    • 4.4.2. Information on Designations Awarded
    • 4.4.3. Other Therapeutic Indications under Evaluation
  • 4.5. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Contributions from Academia
  • 4.6. Stem Cell Therapies for Stroke

5. UNMET NEED ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Unmet Needs Analysis in Stem Cell Therapies for Cardiovascular and Metabolic Disorders Market
    • 5.2.1. Analysis of Data from Patient Blogs
      • 5.2.1.1. Methodology
      • 5.2.1.2. Key Insights: Cardiovascular Disorders
      • 5.2.1.3. Key Insights: Metabolic Disorders
    • 5.2.2. Analysis of Data from Published Literature
      • 5.2.2.1. Methodology
      • 5.2.2.2. Key Insights
        • 5.2.2.2.1. Unmet Needs by Type of Indication
        • 5.2.2.2.2. Unmet Needs by Stem Cell Lineage
    • 5.2.3. Analysis of Data from Social Media Platforms
      • 5.2.3.1. Methodology
      • 5.2.3.2. Key Insights: Cardiovascular Disorders
      • 5.2.3.3. Key Insights: Metabolic Disorders
    • 5.2.4. Expert Opinions
      • 5.2.4.1. Cardiovascular Disorders
        • 5.2.4.1.1. Charles E Murry, Institute for Stem Cell and Regenerative Medicine
        • 5.2.4.1.2. Stuart Conolly, McMaster University
        • 5.2.4.1.3. Akshay Desai, Harvard Medical School; Sheryl Chow, Western University of Health Sciences College of Pharmacy; Scott Solomon, Harvard Medical School; Orly Vardeny, William S. Middleton Memorial VA Hospital
        • 5.2.4.1.4. Naser M Ammash, Mayo Clinic and Joseph A Dearani, Mayo Clinic
        • 5.2.4.1.5. Julie Anne Mitchell, Heart Foundation
        • 5.2.4.1.6. Andre Terzic, Mayo Clinic and Atta Behfar, Mayo Clinic
      • 5.2.4.2. Metabolic Disorders
        • 5.2.4.2.1. Heather A Lau, Lysosomal Storage Disease Program, NYU Langone
        • 5.2.4.2.2. Larry Hirsch, BD Diabetes Care
        • 5.2.4.2.3. Michael Hirst, International Diabetes Federation; David Strain, University of Exeter Medical School in the UK; Xavier Cos, Sant Marti de Provençals Primary Care Centres
    • 5.2.5. Summary of Key Unmet Needs in Cardiovascular and Metabolic Disorders

6. KEY THERAPEUTIC AREAS

  • 6.1. Chapter Overview
  • 6.2. Cardiovascular Disorders
    • 6.2.1. Heart Failure
      • 6.2.1.1. Overview
      • 6.2.1.2. Epidemiology
      • 6.2.1.3. Current Treatment Landscape
        • 6.2.1.3.1. Pharmacological Interventions
        • 6.2.1.3.2. Therapeutic Devices
        • 6.2.1.3.3. Surgery
      • 6.2.1.4. Stem Cell Therapies for Heart Failure
    • 6.2.2. Myocardial Infarction
      • 6.2.2.1. Overview
      • 6.2.2.2. Epidemiology
      • 6.2.2.3. Current Treatment Landscape
        • 6.2.2.3.1. Pharmacological Interventions
        • 6.2.2.3.2. Surgery
      • 6.2.2.4. Stem Cell Therapies for Myocardial Infarction
    • 6.2.3. Critical Limb Ischemia
      • 6.2.3.1. Overview
      • 6.2.3.2. Epidemiology
      • 6.2.3.3. Current Treatment Landscape
        • 6.2.3.3.1. Pharmacological Interventions
        • 6.2.3.3.2. Endovascular Treatments
        • 6.2.3.3.3. Surgery
      • 6.2.3.4. Stem Cell Therapies for Critical Limb Ischemia
  • 6.3. Metabolic Disorders
    • 6.3.1. Diabetes
      • 6.3.1.1. Overview
      • 6.3.1.2. Epidemiology
      • 6.3.1.3. Current Treatment Landscape
        • 6.3.1.3.1. Insulin Therapies
        • 6.3.1.3.2. Non-Insulin Therapies
        • 6.3.1.3.3. Surgery
      • 6.3.1.4. Stem Cell Therapies for Diabetes

7. COMPANY COMPETITIVENESS ANALYSIS

  • 7.1 Chapter Overview
  • 7.2 Methodology
  • 7.3 Assumptions and Key Parameters
  • 7.4 Competitiveness Analysis
    • 7.4.1. Companies Developing Stem Cell Therapies for Cardiovascular Disorders
      • 7.4.1.1. Autologous Stem Cell Therapies
      • 7.4.1.2. Allogenic Stem Cell Therapies
    • 7.5.1. Company Developing Stem Cell Therapies for Metabolic Disorders
      • 7.5.1.1. Autologous Stem Cell Therapies
      • 7.5.1.2. Allogenic Stem Cell Therapies

8. PARTNERSHIPS AND COLLABORATIONS

  • 8.1. Chapter Overview
  • 8.2. Partnership Models
  • 8.3. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: List of Partnerships and Collaborations
    • 8.3.1. Analysis by Year of Partnerships
    • 8.3.2. Analysis by Type of Partnership
    • 8.3.3. Analysis by Therapeutic Area
    • 8.3.4. Regional Analysis
    • 8.3.5. Most Active Players: Analysis by Number of Partnerships

9. FUNDING AND INVESTMENT ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Types of Funding
  • 9.3. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Funding and Investment Analysis
    • 9.3.1. Analysis by Number of Instances
    • 9.3.2. Analysis by Amount Invested
    • 9.3.3. Analysis by Type of Funding
    • 9.3.4. Analysis by Number of Funding Instances and Amount Invested across Different Therapeutic Areas
    • 9.3.5. Analysis by Number of Funding Instances and Amount Invested across Different Type of Stem Cells
    • 9.3.6. Most Active Players
    • 9.3.7. Most Active Investors
  • 9.4. Concluding Remarks

10. PUBLICATION ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Methodology
  • 10.3. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: List of Publications
    • 10.3.1. Analysis by Year of Publication
    • 10.3.2. Analysis by Key Journals
    • 10.3.3. Analysis by Type of Study
    • 10.3.4. Analysis by Type of Disorder
      • 10.3.4.1. Cardiovascular Disorders
      • 10.3.4.2. Metabolic Disorders
    • 10.3.5. Analysis by Stem Cell Lineage
    • 10.3.6. Analysis by Stem Cell Lineage and Focused Indication
    • 10.3.7. Emerging Areas of Focus

11. STEM CELL THERAPIES FOR CARDIOVASCULAR DISORDERS: THERAPY PROFILES

  • 11.1. Chapter Overview
  • 11.2. Stempeucel® (Stempeutics Research)
    • 11.2.1. Therapy Overview
    • 11.2.2. History of Development
    • 11.2.3. Technology Overview
    • 11.2.4. Current Development Status
    • 11.2.5. Key Clinical Trial Results
    • 11.2.6. Dosing, Price and Manufacturing
  • 11.3. Autologous Bone Marrow Concentrate (aBMC) (Cesca Therapeutics)
    • 11.3.1. Therapy Overview
    • 11.3.2. History of Development
    • 11.3.3. Technology Overview
    • 11.3.4. Current Development Status
    • 11.3.5. Key Clinical Trial Results
  • 11.4. BCDA-01 (BioCardia)
    • 11.4.1. Therapy Overview
    • 11.4.2. History of Development
    • 11.4.3. Technology Overview
    • 11.4.4. Current Development Status
    • 11.4.5. Key Clinical Trial Results
  • 11.5. BCDA-02 (BioCardia)
    • 11.5.1. Therapy Overview
    • 11.5.2. History of Development
    • 11.5.3. Technology Overview
    • 11.5.4. Current Development Status
    • 11.5.5. Key Clinical Trial Results
  • 11.6. CLBS14-NORDA (Caladrius Biosciences)
    • 11.6.1. Therapy Overview
    • 11.6.2. History of Development
    • 11.6.3. Technology Overview
    • 11.6.4. Current Development Status
    • 11.6.5. Key Clinical Trial Results
  • 11.7. MPC-150-IM (Mesoblast)
    • 11.7.1. Therapy Overview
    • 11.7.2. History of Development
    • 11.7.3. Technology Overview
    • 11.7.4. Current Development Status
    • 11.7.5. Key Clinical Trial Results
  • 11.8. PLX-PAD (Pluristem Therapeutics)
    • 11.8.1. Therapy Overview
    • 11.8.2. History of Development
    • 11.8.3. Technology Overview
    • 11.8.4. Current Development Status
    • 11.8.5. Key Clinical Trial Results

12. STEM CELL THERAPIES FOR METABOLIC DISORDERS: THERAPY PROFILES

  • 12.1. Chapter Overview
  • 12.2. Strimvelis® (Orchard Therapeutics)
    • 12.2.1. Therapy Overview
    • 12.2.2. History of Development
    • 12.2.3. Technology Overview
    • 12.2.4. Current Development Status
    • 12.2.5. Key Clinical Trial Results
    • 12.2.6. Dosing, Price and Manufacturing
  • 12.3. OTL-200 (Orchard Therapeutics)
    • 12.3.1. Therapy Overview
    • 12.3.2. History of Development
    • 12.3.3. Technology Overview
    • 12.3.4. Current Development Status
    • 12.3.5. Key Clinical Trial Results
  • 12.4. Stem Cell Therapy (Global Cell Med)
    • 12.4.1. Therapy Overview
    • 12.4.2. History of Development
    • 12.4.3. Technology Overview
    • 12.4.4. Current Development Status
    • 12.4.5. Key Clinical Trial Results
  • 12.5. LMSCs (Longeveron)
    • 12.5.1. Therapy Overview
    • 12.5.2. History of Development
    • 12.5.3. Current Development Status
  • 12.6. Stem Cell Educator Therapy (Tianhe Stem Cell Biotechnologies)
    • 12.6.1. Therapy Overview
    • 12.6.2. History of Development
    • 12.6.3. Technology Overview
    • 12.6.4. Current Development Status
    • 12.6.5. Key Clinic Trial Results

13. MARKET FORECAST

  • 13.1. Chapter Overview
  • 13.2. Forecast Methodology and Key Assumptions
  • 13.3. Overall Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders, 2019-2030
    • 13.3.1. Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Therapeutic Area, 2019-2030
    • 13.3.2. Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells, 2019-2030
    • 13.3.3. Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Geography, 2019-2030
  • 13.4. Stem Cell Therapies Market for Cardiovascular Disorders: Overall Market, 2019-2030
    • 13.4.1. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Indication, 2019-2030
    • 13.4.2. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Source of Stem Cells, 2019-2030
    • 13.4.3. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Route of Administration, 2019-2030
    • 13.4.4. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Type of Stem Cells, 2019-2030
    • 13.4.5. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Stem Cell Lineage, 2019-2030
    • 13.4.6. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Geography, 2019-2030
    • 13.4.7. Stem Cell Therapies Market for Cardiovascular Disorders: Myocardial Infarction, 2019-2030
      • 13.4.7.1. Target Patient Population
      • 13.4.7.2. Cellgram®-AMI (Pharmicell)
        • 13.4.7.2.1. Sales Forecast
        • 13.4.7.2.2. Sales Forecast by Geography
      • 13.4.7.3. Cardiocell® (Cytopeutics)
        • 13.4.7.3.1. Sales Forecast
        • 13.4.7.3.2. Sales Forecast by Geography
    • 13.4.8. Stem Cell Therapies Market for Cardiovascular Disorders: Heart Failure, 2019-2030
      • 13.4.8.1. Target Patient Population
      • 13.4.8.2. HeartSheet® (Terumo BCT)
        • 13.4.8.2.1. Sales Forecast
        • 13.4.8.2.2. Sales Forecast by Geography
      • 13.4.8.3. BCDA-01 (BioCardia)
        • 13.4.8.3.1. Sales Forecast
        • 13.4.8.3.2. Sales Forecast by Geography
      • 13.4.8.4. MPC-150-IM (Mesoblast)
        • 13.4.8.4.1. Sales Forecast
        • 13.4.8.4.2. Sales Forecast by Geography
      • 13.4.8.5. Cardiocell® (Cytopeutics)
        • 13.4.8.5.1. Sales Forecast
        • 13.4.8.5.2. Sales Forecast by Geography
      • 13.4.8.6. MyoCell® (U.S. Stem Cell)
        • 13.4.8.6.1. Sales Forecast
        • 13.4.8.6.2. Sales Forecast by Geography
    • 13.4.9. Stem Cell Therapies Market for Cardiovascular Disorders: Critical Limb Ischemia, 2019-2030
      • 13.4.9.1. Target Patient Population
      • 13.4.9.2. Stempeucel® (Stempeutics Research)
        • 13.4.9.2.1. Sales Forecast
        • 13.4.9.2.2. Sales Forecast by Geography
      • 13.4.9.3. aBMC (Cesca Therapeutics)
        • 13.4.9.3.1. Sales Forecast
        • 13.4.9.3.2. Sales Forecast by Geography
      • 13.4.9.4. PLX-PAD (Pluristem Therapeutics)
        • 13.4.9.4.1. Sales Forecast
        • 13.4.9.4.2. Sales Forecast by Geography
      • 13.4.9.5. Cardiocell® (Cytopeutics)
        • 13.4.9.5.1. Sales Forecast
        • 13.4.9.5.2. Sales Forecast by Geography
    • 13.4.10. Stem Cell Therapies Market for Cardiovascular Disorders: Other Indications, 2019-2030
      • 13.4.10.1. Target Patient Population
      • 13.4.10.2. BCDA-02 (BioCardia)
        • 13.4.10.2.1. Sales Forecast
        • 13.4.10.2.2. Sales Forecast by Geography
      • 13.4.10.3. CLBS14-NORDA (Caladrius Biosciences )
        • 13.4.10.3.1. Sales Forecast
        • 13.4.10.3.2. Sales Forecast by Geography
      • 13.4.10.4. Cardiocell® (Cardiocell)
        • 13.4.10.4.1. Sales Forecast
        • 13.4.10.4.2. Sales Forecast by Geography
  • 13.5. Stem Cell Therapies Market for Metabolic Disorders: Overall Market, 2019-2030
    • 13.5.1. Stem Cell Therapies Market for Metabolic Disorders: Distribution by Indication, 2019-2030
    • 13.5.2. Stem Cell Therapies Market for Metabolic Disorders: Distribution by Source of Stem Cells, 2019-2030
    • 13.5.3. Stem Cell Therapies Market for Metabolic Disorders: Distribution by Route of Administration, 2019-2030
    • 13.5.4. Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cells, 2019-2030
    • 13.5.5. Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cell Lineage, 2019-2030
    • 13.5.6. Stem Cell Therapies Market for Metabolic Disorders: Distribution by Geography, 2019-2030
    • 13.5.7. Stem Cell Therapies Market for Metabolic Disorders: ADA-SCID, 2019-2030
      • 13.5.7.1. Target Patient Population
      • 13.5.7.2. Strimvelis® (Orchard Therapeutics)
        • 13.5.7.2.1. Sales Forecast
        • 13.5.7.2.2. Sales Forecast by Geography
    • 13.5.8. Stem Cell Therapies Market for Metabolic Disorders: Metachromatic Leukodystrophy, 2019-2030
      • 13.5.8.1. Target Patient Population
      • 13.5.8.2. OTL-200 (Orchard Therapeutics)
        • 13.5.8.2.1. Sales Forecast
        • 13.5.8.2.2. Sales Forecast by Geography
    • 13.5.9. Stem Cell Therapies Market for Metabolic Disorders: Type 1 Diabetes, 2019-2030
      • 13.5.9.1. Target Patient Population
      • 13.5.9.2. Unnamed Stem Cell Therapy by Global Cell Med
        • 13.5.9.2.1. Sales Forecast
        • 13.5.9.2.2. Sales Forecast by Geography

14. CONCLUSION

  • 14.1. The Treatment Landscape of Cardiovascular and Metabolic Disorders is Characterized by Several Unmet Needs; Stem Cell Therapies have Demonstrated the Potential to Offer Viable and Lasting Therapeutic Effect
  • 14.2. The Market Features a Promising Pipeline with Several Mid and Late Stage Product Therapies, which are Mostly based on Stem Cells Derived from Adults
  • 14.3. The Fragmented Developer Landscape Includes Small, Mid-Sized and Established Players; the Majority of Stakeholders are Presently based in North America and Europe
  • 14.4. The Heightened Pace of Research in this Field is Evident in Multiple R&D Agreements Inked and the Rise in Number of Scientific Articles Published in the Recent Years
  • 14.5. Development Efforts in this Field have Garnered the Attention of Various Private and Public Investors, Resulting in Significant Capital Investments, which are Likely to Provide the Necessary Boost to the Market's Future Growth
  • 14.6. Given the Impending Approval of Multiple Late Stage Molecules, the Market is Poised to Grow at a Significant Pace in the Coming Years

15. EXECUTIVE INSIGHTS

  • 15.1. Chapter Overview
  • 15.2. Kadimastem
    • 15.2.1. Company Snapshot
    • 15.2.2. Interview Transcript: Michel Revel, Chief Scientist and Galit Mazooz-Perlmuter, Business Development Manager
  • 15.3. Xcelthera
    • 15.3.1. Company Snapshot
    • 15.3.2. Interview Transcript: Xuejun H Parsons, Chief Executive Officer

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

  • Figure 3.1: Stem Cell Therapies: Process of Therapy Development and Administration
  • Figure 3.2: Classification of Stem Cell Therapies by Type of Cells
  • Figure 3.3: Potential Application Areas for Stem Cell Therapies
  • Figure 4.1: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Target Therapeutic Area
  • Figure 4.2: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Phase of Development
  • Figure 4.3: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells
  • Figure 4.4: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Stem Cells
  • Figure 4.5: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Stem Cell Lineage
  • Figure 4.6: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Route of Administration
  • Figure 4.7: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Cardiovascular Disorder
  • Figure 4.8: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Metabolic Disorder
  • Figure 4.9: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Key Developers
  • Figure 4.10: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Target Indication and Phase of Development
  • Figure 4.11: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Grid Analysis
  • Figure 4.12: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Focus Area of Developer
  • Figure 4.13: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Year of Establishment of Developer
  • Figure 4.14: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Size of Developer
  • Figure 4.15: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Geographical Location of Developer
  • Figure 4.16: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Size and Geographical Location of Developer
  • Figure 4.17: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Mapping Regional Activity
  • Figure 4.18: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Logo Landscape
  • Figure 4.19: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Designations Awarded to Stem Cell Therapies
  • Figure 5.1: Unmet Needs Analysis: Overview of Methodology
  • Figure 5.2: Unmet Needs in Cardiovascular Disorders: Word Cloud Analysis of Data from Patient Blogs
  • Figure 5.3: Unmet Needs in Metabolic Disorders: Word Cloud Analysis of Data from Patient Blogs
  • Figure 5.4: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature
  • Figure 5.5: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Type and Year
  • Figure 5.6: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Type of Indication
  • Figure 5.7: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Stem Cell Lineage
  • Figure 5.8: Unmet Needs in Stem Cell Therapies for Cardiovascular Disorders: Word Cloud Analysis of Data from Social Media Tweets
  • Figure 5.9: Unmet Needs in Stem Cell Therapies for Metabolic Disorders: Word Cloud Analysis of Data from Social Media Tweets
  • Figure 5.10: Key Unmet Needs in Cardiovascular Disorders
  • Figure 5.11: Key Unmet Needs in Metabolic Disorders
  • Figure 6.1: Key Therapeutic Indications
  • Figure 6.2: Heart Failure: Types
  • Figure 6.3: Heart Failure: Symptoms
  • Figure 6.4: Heart Failure: Risk Factors
  • Figure 6.5: Heart Failure: Distribution of Stem Cell Therapies by Phase of Development and Type of Stem Cells
  • Figure 6.6: Myocardial Infarction: Risk Factors
  • Figure 6.7: Myocardial Infarction: Distribution by Phase of Development and Type of Stem Cells
  • Figure 6.8: Critical Limb Ischemia: Symptoms
  • Figure 6.9: Critical Limb Ischemia: Risk Factors
  • Figure 6.10: Critical Limb Ischemia: Distribution of Stem Cell Therapies by Phase of Development and Type of Stem Cells
  • Figure 6.11: Diabetes: Risk Factors
  • Figure 6.12: Diabetes: Currently Available Non-Insulin Therapies
  • Figure 6.13: Diabetes: Distribution by Phase of Development and Type of Stem Cells
  • Figure 7.1: Competitiveness Analysis of Companies Developing Stem Cell Therapies for Cardiovascular Disorders
  • Figure 7.2: Competitiveness Analysis of Companies Developing Autologous Stem Cell Therapies for Cardiovascular Disorders
  • Figure 7.3: Competitiveness Analysis of Companies Developing Allogenic Stem Cell Therapies for Cardiovascular Disorders
  • Figure 7.4: Competitiveness Analysis of Companies Developing Stem Cell Therapies for Metabolic Disorders
  • Figure 7.5: Competitiveness Analysis of Companies Developing Autologous Stem Cell Therapies for Metabolic Disorders
  • Figure 7.6: Competitiveness Analysis of Companies Developing Allogenic Stem Cell Therapies for Metabolic Disorders
  • Figure 8.1: Partnerships and Collaborations: Cumulative Trend by Year, 2012-2018
  • Figure 8.2: Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 8.3: Partnerships and Collaborations: Distribution by Year of Partnership and Therapeutic Area
  • Figure 8.4: Partnerships and Collaborations: Distribution by Type of Partnership, 2012-2015 and Post 2015
  • Figure 8.5: Partnerships and Collaborations : Activity of Big Pharmaceutical Companies
  • Figure 8.6: Partnerships and Collaborations: Regional Distribution
  • Figure 8.7: Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Figure 8.8: Partnerships and Collaborations: Most Active Players
  • Figure 9.1: Funding and Investments: Distribution by Type of Funding and Year, 2012-2018
  • Figure 9.2: Funding and Investments: Cumulative Number of Instances by Year, 2012-2018
  • Figure 9.3: Funding and Investments: Cumulative Amount Invested by Year, 2012-2018 (USD Million)
  • Figure 9.4: Funding and Investments: Distribution by Type of Funding
  • Figure 9.5: Funding and Investments: Distribution of Total Amount Invested by Type of Funding (USD Million)
  • Figure 9.6: Funding and Investments: Distribution of Number of Funding Instances by Year across Major Therapeutic Areas, 2012-2018
  • Figure 9.7: Funding and Investments: Amount Invested by Year across Major Therapeutic Areas, 2012-2018
  • Figure 9.8: Funding and Investments: Distribution of Number of Instances by Type of Funding, 2012-2015 and Post 2015
  • Figure 9.9: Funding and Investments: Amount Invested by Type of Funding, 2012-2015 and Post 2015
  • Figure 9.10: Funding and Investments: Amount Invested by Year of Investments in Various Type of Stem Cells, 2012-2018
  • Figure 9.11: Funding and Investments: Most Active Players
  • Figure 9.12: Funding and Investments: Most Active Investors
  • Figure 9.13: Funding and Investments Summary
  • Figure 10.1: Publications: Cumulative Trend by Year, 2013-2018
  • Figure 10.2: Publications: Most Popular Journals
  • Figure 10.3: Publications: Distribution by Type of Study
  • Figure 10.4: Publications: Distribution by Type of Disorder
  • Figure 10.5: Publications: Distribution by Type of Cardiovascular Disorders
  • Figure 10.6: Publications: Distribution by Type of Metabolic Disorders
  • Figure 10.7: Publications: Distribution by Stem Cell Lineage
  • Figure 10.8: Publications: Distribution of Articles Focused on Bone Marrow Derived Stem Cells by Indication
  • Figure 10.9: Publications: Distribution of Articles Focused on Cardiosphere Derived Stem Cells by Indication
  • Figure 10.10: Publications: Distribution of Articles Focused on Adipose Derived Stem Cells by Indication
  • Figure 10.11: Publications: Emerging Areas
  • Figure 11.1: Stempeucel®: History of Development
  • Figure 11.2: Stempeucel®: Development / Manufacturing Process
  • Figure 11.3: aBMC by Cesca Therapeutics: History of Development
  • Figure 11.4: aBMC by Cesca Therapeutics: Development / Manufacturing Process
  • Figure 11.5: BCDA-01: History of Development
  • Figure 11.6: BCDA-01: Development / Manufacturing Process
  • Figure 11.7: BCDA-02: History of Development
  • Figure 11.8: BCDA-02: Development / Manufacturing Process
  • Figure 11.9: CLBS14-NORDA: History of Development
  • Figure 11.10: CLBS14-NORDA: Development / Manufacturing Process
  • Figure 11.11: MPC-150-IM: History of Development
  • Figure 11.12: MPC-150-IM: Development / Manufacturing Process
  • Figure 11.13: PLX-PAD: Mechanism of Action
  • Figure 11.14: PLX-PAD: History of Development
  • Figure 11.15: PLX-PAD: Development / Manufacturing Process
  • Figure 12.1: Strimvelis®: History of Development
  • Figure 12.2: Strimvelis®: Development / Manufacturing Process
  • Figure 12.3: OTL-200: Development / Manufacturing Process
  • Figure 12.4: Unnamed Stem Cell Therapy by Global Cell Med: Development / Manufacturing Process
  • Figure 12.5: Stem Cell Educator System: History of Development
  • Figure 12.6: Stem Cell Educator System: Development / Manufacturing Process
  • Figure 13.1: Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Overall Market, 2019-2030 (USD Million)
  • Figure 13.2: Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Therapeutic Area, 2019-2030 (USD Million)
  • Figure 13.3: Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells, 2019-2030 (USD Million)
  • Figure 13.4: Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Geography, 2019-2030 (USD Million)
  • Figure 13.5: Stem Cell Therapies Market for Cardiovascular Disorders: Overall Market, 2019-2030 (USD Million)
  • Figure 13.6: Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Indication, 2019-2030 (USD Million)
  • Figure 13.7: Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Source of Stem Cells, 2019-2030 (USD Million)
  • Figure 13.8: Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Route of Administration, 2019-2030 (USD Million)
  • Figure 13.9: Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Type of Stem Cells, 2019-2030 (USD Million)
  • Figure 13.10: Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Stem Cell Lineage, 2019-2030 (USD Million)
  • Figure 13.11: Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Geography, 2019-2030 (USD Million)
  • Figure 13.12: Cellgram®-AMI: Sales Forecast for Myocardial Infarction, Till 2030 (USD Million)
  • Figure 13.13: Cellgram®-AMI: Sales Forecast by Geography for Myocardial Infarction, Till 2030 (USD Million)
  • Figure 13.14: Cardiocell®: Sales Forecast for Myocardial Infarction, Till 2030 (USD Million)
  • Figure 13.15: Cardiocell®: Sales Forecast by Geography for Myocardial Infarction, Till 2030 (USD Million)
  • Figure 13.16: HeartSheet®: Sales Forecast for Heart Failure, Till 2030 (USD Million)
  • Figure 13.17: HeartSheet®: Sales Forecast by Geography for Heart Failure, Till 2030 (USD Million)
  • Figure 13.18: BCDA-01: Sales Forecast for Heart Failure, Till 2030 (USD Million)
  • Figure 13.19: BCDA-01: Sales Forecast by Geography for Heart Failure, Till 2030 (USD Million)
  • Figure 13.20: MPC-150-IM (Rexlemestrocel-L): Sales Forecast for Heart Failure, Till 2030 (USD Million)
  • Figure 13.21: MPC-150-IM (Rexlemestrocel-L): Sales Forecast by Geography for Heart Failure, Till 2030 (USD Million)
  • Figure 13.22: Cardiocell®: Sales Forecast for Heart Failure, Till 2030 (USD Million)
  • Figure 13.23: Cardiocell®: Sales Forecast by Geography for Heart Failure, Till 2030 (USD Million)
  • Figure 13.24: MyoCell®: Sales Forecast for Heart Failure, Till 2030 (USD Million)
  • Figure 13.25: MyoCell®: Sales Forecast by Geography for Heart Failure, Till 2030 (USD Million)
  • Figure 13.26: Stempeucel®: Sales Forecast for Critical Limb Ischemia, Till 2030 (USD Million)
  • Figure 13.27: Stempeucel®: Sales Forecast by Geography for Critical Limb Ischemia, Till 2030 (USD Million)
  • Figure 13.28: aBMC by Cesca Therapeutics: Sales Forecast for Critical Limb Ischemia, Till 2030 (USD Million)
  • Figure 13.29: aBMC by Cesca Therapeutics: Sales Forecast by Geography for Critical Limb Ischemia, Till 2030 (USD Million)
  • Figure 13.30: PLX-PAD: Sales Forecast for Critical Limb Ischemia, Till 2030 (USD Million)
  • Figure 13.31: PLX-PAD: Sales Forecast by Geography for Critical Limb Ischemia, Till 2030 (USD Million)
  • Figure 13.32: Cardiocell®: Sales Forecast for Critical Limb Ischemia, Till 2030 (USD Million)
  • Figure 13.33: Cardiocell®: Sales Forecast by Geography for Critical Limb Ischemia, Till 2030 (USD Million)
  • Figure 13.34: BCDA-02: Sales Forecast for Other Cardiovascular Indications, Till 2030 (USD Million)
  • Figure 13.35: BCDA-02: Sales Forecast by Geography for Other Cardiovascular Indications, Till 2030 (USD Million)
  • Figure 13.36: CLBS14-NORDA: Sales Forecast for Other Cardiovascular Indications, Till 2030 (USD Million)
  • Figure 13.37: CLBS14-NORDA: Sales Forecast by Geography for Other Cardiovascular Indications, Till 2030 (USD Million)
  • Figure 13.38: Cardiocell®: Sales Forecast for Other Cardiovascular Indications, Till 2030 (USD Million)
  • Figure 13.39: Cardiocell®: Sales Forecast by Geography for Other Cardiovascular Indications, Till 2030 (USD Million)
  • Figure 13.40: Stem Cell Therapies Market for Metabolic Disorders: Overall Market, 2019-2030 (USD Million)
  • Figure 13.41: Stem Cell Therapies Market for Metabolic Disorders: Distribution by Indication, 2019-2030 (USD Million)
  • Figure 13.42: Stem Cell Therapies Market for Metabolic Disorders: Distribution by Source of Stem Cells, 2019-2030 (USD Million)
  • Figure 13.43: Stem Cell Therapies Market for Metabolic Disorders: Distribution by Route of Administration, 2019-2030 (USD Million)
  • Figure 13.44: Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cells, 2019-2030 (USD Million)
  • Figure 13.45: Stem Cell Therapies Market for Metabolic Disorders: Distribution by Stem Cell Lineage, 2019-2030 (USD Million)
  • Figure 13.46: Stem Cell Therapies Market for Metabolic Disorders: Distribution by Geography, 2019-2030 (USD Million)
  • Figure 13.47: Strimvelis®: Sales Forecast for ADA-SCID, Till 2030 (USD Million)
  • Figure 13.48: Strimvelis®: Sales Forecast by Geography for ADA-SCID, Till 2030 (USD Million)
  • Figure 13.49: OTL-200: Sales Forecast for Metachromatic Leukodystrophy, Till 2030 (USD Million)
  • Figure 13.50: OTL-200: Sales Forecast by Geography for Metachromatic Leukodystrophy, Till 2030 (USD Million)
  • Figure 13.51: Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast for Type 1 Diabetes, Till 2030 (USD Million)
  • Figure 13.52: Unnamed Stem Cell Therapy by Global Cell Med : Sales Forecast by Geography for Type 1 Diabetes, Till 2030 (USD Million)
  • Figure 14.1: Overall Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Conservative, Base and Optimistic Forecast Scenarios, 2020 and 2030 (USD Million)

List of Tables

  • Table 4.1: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Marketed and Development Pipeline (Industry Players)
  • Table 4.2: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Developer Overview
  • Table 4.3: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Information on Dose of Stem Cell Therapies
  • Table 4.4: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Information on Designations Awarded to Stem Cell Therapies
  • Table 4.5: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Other Indications Under Evaluation
  • Table 4.6: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Pipeline Overview (Academic Players)
  • Table 4.7: Stem Cell Therapies for Stroke
  • Table 5.1: Unmet Needs in Stem Cell Therapies for Cardiovascular and Metabolic Disorders: List of Blog Portals
  • Table 6.1: Heart Failure: List of Marketed Drugs
  • Table 6.2: Heart Failure: List of Stem Cell Therapies
  • Table 6.3: Myocardial Infarction: List of Marketed Drugs
  • Table 6.4: Myocardial Infarction: List of Stem Cell Therapies
  • Table 6.5: Peripheral Arterial Diseases: List of Marketed Drugs
  • Table 6.6: Critical Limb Ischemia: List of Stem Cell Therapies
  • Table 6.7: Diabetes: Current Treatment Landscape
  • Table 6.8: Diabetes: List of Stem Cell Therapies
  • Table 8.1: Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Partnerships and Collaborations, 2012-2018
  • Table 9.1: Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Funding and Investments, 2012-2018
  • Table 9.2: Funding and Investment Analysis: Summary of Investments
  • Table 10.1: Stem Cell Therapy for Cardiovascular and Metabolic Disorders: List of Publications, 2013-2018
  • Table 11.1: Stempeutics: Clinical Trials
  • Table 11.2: aBMC by Cesca Therapeutics: Clinical Trials
  • Table 11.3: BCDA-01: Clinical Trials
  • Table 11.4: BCDA-02: Clinical Trials
  • Table 11.5: CLBS14-NORDA: Clinical Trials
  • Table 11.6: MPC-150-IM: Clinical Trials
  • Table 11.7: PLX-PAD: Clinical Trials
  • Table 12.1: Strimvelis: Clinical Trials
  • Table 12.2: Stem Cell Therapy by Global Cell Med: Clinical Trials
  • Table 12.3: LMSCs: Clinical Trials
  • Table 12.4: Stem Cell Educator Therapy: Clinical Trials
  • Table 15.1: Kadimastem: Key Highlights
  • Table 15.2: Xcelthera: Key Highlights
  • Table 16.1: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Target Therapeutic Area
  • Table 16.2: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Phase of Development
  • Table 16.3: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells
  • Table 16.4: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Stem Cells
  • Table 16.5: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Stem Cell Lineage
  • Table 16.6: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Route of Administration
  • Table 16.7: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Cardiovascular Disorder
  • Table 16.8: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Metabolic Disorder
  • Table 16.9: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Focus Area of Developer
  • Table 16.10: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Year of Establishment of Developer
  • Table 16.11: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Size of Developer
  • Table 16.12: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Geographical Location of Developer
  • Table 16.13: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature
  • Table 16.14: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Type and Year
  • Table 16.15: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Type of Indication
  • Table 16.16: Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Stem Cell Lineage
  • Table 16.17: Partnerships and Collaborations: Cumulative Trend by Year, 2012-2018
  • Table 16.18: Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 16.19: Partnerships and Collaborations: Distribution by Year of Partnership and Therapeutic Area
  • Table 16.20: Partnerships and Collaborations: Distribution by Type of Partnership, 2012-2015 and Post 2015
  • Table 16.21: Partnerships and Collaborations: Regional Distribution
  • Table 16.22: Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Table 16.23: Funding and Investments: Distribution by Type of Funding and Year, 2012-2018
  • Table 16.24: Funding and Investments: Cumulative Number of Instances by Year, 2012-2018
  • Table 16.25: Funding and Investments: Cumulative Amount Invested by Year, 2012-2018 (USD Million)
  • Table 16.26: Funding and Investments: Distribution by Type of Funding
  • Table 16.27: Funding and Investments: Distribution of Total Amount Invested by Type of Funding (USD Million)
  • Table 16.28: Funding and Investments: Distribution of Number of Funding Instances by Year across Major Therapeutic Areas, 2012-2018
  • Table 16.29: Funding and Investments: Amount Invested by Year across Major Therapeutic Areas, 2012-2018
  • Table 16.30: Funding and Investments: Distribution of Number of Instances by Type of Funding, 2012-2015 and Post 2015
  • Table 16.31: Funding and Investments: Amount Invested by Type of Funding, 2012-2015 and Post 2015
  • Table 16.32: Funding and Investments: Amount Invested by Year of Investments in Various Type of Stem Cells, 2012-2018
  • Table 16.33: Publications: Cumulative Trend by Year, 2013-2018
  • Table 16.34: Publications: Distribution by Type of Study
  • Table 16.35: Publications: Distribution by Type of Disorder
  • Table 16.36: Publications: Distribution by Type of Cardiovascular Disorders
  • Table 16.37: Publications: Distribution by Type of Metabolic Disorders
  • Table 16.38: Publications: Distribution by Stem Cell Lineage
  • Table 16.39: Publications: Distribution of Articles Focused on Bone Marrow Derived Stem Cells by Indication
  • Table 16.40: Publications: Distribution of Articles Focused on Cardiosphere Derived Stem Cells by Indication
  • Table 16.41: Publications: Distribution of Articles Focused on Adipose Derived Stem Cells by Indication
  • Table 16.42: Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Overall Market, Conservative Scenario, 2019-2030 (USD Million)
  • Table 16.43: Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Overall Market, Base Scenario, 2019-2030 (USD Million)
  • Table 16.44: Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Overall Market, Opportunistic Scenario, 2019-2030 (USD Million)
  • Table 16.45: Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Therapeutic Area, Conservative Scenario, 2019-2030 (USD Million)
  • Table 16.46: Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Therapeutic Area, Base Scenario, 2019-2030 (USD Million)
  • Table 16.47: Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Therapeutic Area, Opportunistic Scenario, 2019-2030 (USD Million)
  • Table 16.48: Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells, Conservative Scenario, 2019-2030 (USD Million)
  • Table 16.49: Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells, Base Scenario, 2019-2030 (USD Million)
  • Table 16.50: Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells, Opportunistic Scenario, 2019-2030 (USD Million)
  • Table 16.51: Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Geography, Conservative Scenario, 2019-2030 (USD Million)
  • Table 16.52: Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Geography, Base Scenario, 2019-2030 (USD Million)
  • Table 16.53: Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Geography, Opportunistic Scenario, 2019-2030 (USD Million)
  • Table 16.54: Stem Cell Therapies Market for Cardiovascular Disorders: Overall Market, Conservative Scenario, 2019-2030 (USD Million)
  • Table 16.55: Stem Cell Therapies Market for Cardiovascular Disorders: Overall Market, Base Scenario, 2019-2030 (USD Million)
  • Table 16.56: Stem Cell Therapies Market for Cardiovascular Disorders: Overall Market, Opportunistic Scenario, 2019-2030 (USD Million)
  • Table 16.57: Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Indication, Conservative Scenario, 2019-2030 (USD Million)
  • Table 16.58: Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Indication, Base Scenario, 2019-2030 (USD Million)
  • Table 16.59: Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Indication, Opportunistic Scenario, 2019-2030 (USD Million)
  • Table 16.60: Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Source of Stem Cells, Conservative Scenario, 2019-2030 (USD Million)
  • Table 16.61: Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Source of Stem Cells, Base Scenario, 2019-2030 (USD Million)
  • Table 16.62: Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Source of Stem Cells, Opportunistic Scenario, 2019-2030 (USD Million)
  • Table 16.63: Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Route of Administration, Conservative Scenario, 2019-2030 (USD Million)
  • Table 16.64: Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Route of Administration, Base Scenario, 2019-2030 (USD Million)
  • Table 16.65: Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Route of Administration, Opportunistic Scenario, 2019-2030 (USD Million)
  • Table 16.66: Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Type of Stem Cells, Conservative Scenario, 2019-2030 (USD Million)
  • Table 16.67: Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Type of Stem Cells, Base Scenario, 2019-2030 (USD Million)
  • Table 16.68: Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Type of Stem Cells, Opportunistic Scenario, 2019-2030 (USD Million)
  • Table 16.69: Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Stem Cell Lineage, Conservative Scenario, 2019-2030 (USD Million)
  • Table 16.70: Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Stem Cell Lineage, Base Scenario, 2019-2030 (USD Million)
  • Table 16.71: Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Stem Cell Lineage, Opportunistic Scenario, 2019-2030 (USD Million)
  • Table 16.72: Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Geography, Conservative Scenario, 2019-2030 (USD Million)
  • Table 16.73: Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Geography, Base Scenario, 2019-2030 (USD Million)
  • Table 16.74: Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Geography, Opportunistic Scenario, 2019-2030 (USD Million)
  • Table 16.75: Cellgram®-AMI: Sales Forecast for Myocardial Infarction, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.76: Cellgram®-AMI: Sales Forecast for Myocardial Infarction, Base Scenario, Till 2030 (USD Million)
  • Table 16.77: Cellgram®-AMI: Sales Forecast for Myocardial Infarction, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.78: Cellgram®-AMI: Sales Forecast by Geography for Myocardial Infarction, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.79: Cellgram®-AMI: Sales Forecast by Geography for Myocardial Infarction, Base Scenario, Till 2030 (USD Million)
  • Table 16.80: Cellgram®-AMI: Sales Forecast by Geography for Myocardial Infarction, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.81: Cardiocell®: Sales Forecast for Myocardial Infarction, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.82: Cardiocell®: Sales Forecast for Myocardial Infarction, Base Scenario, Till 2030 (USD Million)
  • Table 16.83: Cardiocell®: Sales Forecast for Myocardial Infarction, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.84: Cardiocell®: Sales Forecast by Geography for Myocardial Infarction, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.85: Cardiocell®: Sales Forecast by Geography for Myocardial Infarction, Base Scenario, Till 2030 (USD Million)
  • Table 16.86: Cardiocell®: Sales Forecast by Geography for Myocardial Infarction, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.87: HeartSheet®: Sales Forecast for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.88: HeartSheet®: Sales Forecast for Heart Failure, Base Scenario, Till 2030 (USD Million)
  • Table 16.89: HeartSheet®: Sales Forecast for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.90: HeartSheet®: Sales Forecast by Geography for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.91: HeartSheet®: Sales Forecast by Geography for Heart Failure, Base Scenario, Till 2030 (USD Million)
  • Table 16.92: HeartSheet®: Sales Forecast by Geography for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.93: BCDA-01: Sales Forecast for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.94: BCDA-01: Sales Forecast for Heart Failure, Base Scenario, Till 2030 (USD Million)
  • Table 16.95: BCDA-01: Sales Forecast for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.96: BCDA-01: Sales Forecast by Geography for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.97: BCDA-01: Sales Forecast by Geography for Heart Failure, Base Scenario, Till 2030 (USD Million)
  • Table 16.98: BCDA-01: Sales Forecast by Geography for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.99: MPC-150-IM (Rexlemestrocel-L): Sales Forecast for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.100: MPC-150-IM (Rexlemestrocel-L): Sales Forecast for Heart Failure, Base Scenario, Till 2030 (USD Million)
  • Table 16.101: MPC-150-IM (Rexlemestrocel-L): Sales Forecast for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.102: MPC-150-IM (Rexlemestrocel-L): Sales Forecast by Geography for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.103: MPC-150-IM (Rexlemestrocel-L): Sales Forecast by Geography for Heart Failure, Base Scenario, Till 2030 (USD Million)
  • Table 16.104: MPC-150-IM (Rexlemestrocel-L): Sales Forecast by Geography for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.105: Cardiocell®: Sales Forecast for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.106: Cardiocell®: Sales Forecast for Heart Failure, Base Scenario, Till 2030 (USD Million)
  • Table 16.107: Cardiocell®: Sales Forecast for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.108: Cardiocell®: Sales Forecast by Geography for Heart Failure, Conservative Scenario Till 2030 (USD Million)
  • Table 16.109: Cardiocell®: Sales Forecast by Geography for Heart Failure, Base Scenario Till 2030 (USD Million)
  • Table 16.110: Cardiocell®: Sales Forecast by Geography for Heart Failure, Opportunistic Scenario Till 2030 (USD Million)
  • Table 16.111: MyoCell®: Sales Forecast for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.112: MyoCell®: Sales Forecast for Heart Failure, Base Scenario, Till 2030 (USD Million)
  • Table 16.113: MyoCell®: Sales Forecast for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.114: MyoCell®: Sales Forecast by Geography for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.115: MyoCell®: Sales Forecast by Geography for Heart Failure, Base Scenario, Till 2030 (USD Million)
  • Table 16.116: MyoCell®: Sales Forecast by Geography for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.117: Stempeucel®: Sales Forecast for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.118: Stempeucel®: Sales Forecast for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
  • Table 16.119: Stempeucel®: Sales Forecast for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.120: Stempeucel®: Sales Forecast by Geography for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.121: Stempeucel®: Sales Forecast by Geography for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
  • Table 16.122: Stempeucel®: Sales Forecast by Geography for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.123: aBMC by Cesca Therapeutics: Sales Forecast for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.124: aBMC by Cesca Therapeutics: Sales Forecast for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
  • Table 16.125: aBMC by Cesca Therapeutics: Sales Forecast for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.126: aBMC by Cesca Therapeutics: Sales Forecast by Geography for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.127: aBMC by Cesca Therapeutics: Sales Forecast by Geography for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
  • Table 16.128: aBMC by Cesca Therapeutics: Sales Forecast by Geography for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.129: PLX-PAD: Sales Forecast for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.130: PLX-PAD: Sales Forecast for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
  • Table 16.131: PLX-PAD: Sales Forecast for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.132: PLX-PAD: Sales Forecast by Geography for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.133: PLX-PAD: Sales Forecast by Geography for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
  • Table 16.134: PLX-PAD: Sales Forecast by Geography for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.135: Cardiocell®: Sales Forecast for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.136: Cardiocell®: Sales Forecast for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
  • Table 16.137: Cardiocell®: Sales Forecast for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.138: Cardiocell®: Sales Forecast by Geography for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.139: Cardiocell®: Sales Forecast by Geography for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
  • Table 16.140: Cardiocell®: Sales Forecast by Geography for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.141: BCDA-02: Sales Forecast for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.142: BCDA-02: Sales Forecast for Other Cardiovascular Indications, Base Scenario, Till 2030 (USD Million)
  • Table 16.143: BCDA-02: Sales Forecast for Other Cardiovascular Indications, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.144: BCDA-02: Sales Forecast by Geography for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.145: BCDA-02: Sales Forecast by Geography for Other Cardiovascular Indications, base Scenario, Till 2030 (USD Million)
  • Table 16.146: BCDA-02: Sales Forecast by Geography for Other Cardiovascular Indications, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.147: CLBS14-NORDA: Sales Forecast for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.148: CLBS14-NORDA: Sales Forecast for Other Cardiovascular Indications, Base Scenario, Till 2030 (USD Million)
  • Table 16.149: CLBS14-NORDA: Sales Forecast for Other Cardiovascular Indications, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.150: CLBS14-NORDA: Sales Forecast by Geography for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.151: CLBS14-NORDA: Sales Forecast by Geography for Other Cardiovascular Indications, Base Scenario, Till 2030 (USD Million)
  • Table 16.152: CLBS14-NORDA: Sales Forecast by Geography for Other Cardiovascular Indications, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.153: Cardiocell®: Sales Forecast for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.154: Cardiocell®: Sales Forecast for Other Cardiovascular Indications, Base Scenario, Till 2030 (USD Million)
  • Table 16.155: Cardiocell®: Sales Forecast for Other Cardiovascular Indications, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.156: Cardiocell®: Sales Forecast by Geography for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.157: Cardiocell®: Sales Forecast by Geography for Other Cardiovascular Indications, Base Scenario, Till 2030 (USD Million)
  • Table 16.158: Cardiocell®: Sales Forecast by Geography for Other Cardiovascular Indications, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.159: Stem Cell Therapies Market for Metabolic Disorders: Overall Market, Conservative Scenario, 2019-2030 (USD Million)
  • Table 16.160: Stem Cell Therapies Market for Metabolic Disorders: Overall Market, Base Scenario, 2019-2030 (USD Million)
  • Table 16.161: Stem Cell Therapies Market for Metabolic Disorders: Overall Market, Opportunistic Scenario, 2019-2030 (USD Million)
  • Table 16.162: Stem Cell Therapies Market for Metabolic Disorders: Distribution by Indication, Conservative Scenario, 2019-2030 (USD Million)
  • Table 16.163: Stem Cell Therapies Market for Metabolic Disorders: Distribution by Indication, Base Scenario, 2019-2030 (USD Million)
  • Table 16.164: Stem Cell Therapies Market for Metabolic Disorders: Distribution by Indication, Opportunistic Scenario, 2019-2030 (USD Million)
  • Table 16.165: Stem Cell Therapies Market for Metabolic Disorders: Distribution by Source of Stem Cells, Conservative Scenario, 2019-2030 (USD Million)
  • Table 16.166: Stem Cell Therapies Market for Metabolic Disorders: Distribution by Source of Stem Cells, Base Scenario, 2019-2030 (USD Million)
  • Table 16.167: Stem Cell Therapies Market for Metabolic Disorders: Distribution by Source of Stem Cells, Opportunistic Scenario, 2019-2030 (USD Million)
  • Table 16.168: Stem Cell Therapies Market for Metabolic Disorders: Distribution by Route of Administration, Conservative Scenario, 2019-2030 (USD Million)
  • Table 16.169: Stem Cell Therapies Market for Metabolic Disorders: Distribution by Route of Administration, Base Scenario, 2019-2030 (USD Million)
  • Table 16.170: Stem Cell Therapies Market for Metabolic Disorders: Distribution by Route of Administration, Opportunistic Scenario, 2019-2030 (USD Million)
  • Table 16.171: Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cells, Conservative Scenario, 2019-2030 (USD Million)
  • Table 16.172: Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cells, Base Scenario, 2019-2030 (USD Million)
  • Table 16.173: Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cells, Opportunistic Scenario, 2019-2030 (USD Million)
  • Table 16.174: Stem Cell Therapies Market for Metabolic Disorders: Distribution by Stem Cell Lineage, Conservative Scenario, 2019-2030 (USD Million)
  • Table 16.175: Stem Cell Therapies Market for Metabolic Disorders: Distribution by Stem Cell Lineage, Base Scenario, 2019-2030 (USD Million)
  • Table 16.176: Stem Cell Therapies Market for Metabolic Disorders: Distribution by Stem Cell Lineage, Opportunistic Scenario, 2019-2030 (USD Million)
  • Table 16.177: Stem Cell Therapies Market for Metabolic Disorders: Distribution by Geography, Conservative Scenario, 2019-2030 (USD Million)
  • Table 16.178: Stem Cell Therapies Market for Metabolic Disorders: Distribution by Geography, Base Scenario, 2019-2030 (USD Million)
  • Table 16.179: Stem Cell Therapies Market for Metabolic Disorders: Distribution by Geography, Opportunistic Scenario, 2019-2030 (USD Million)
  • Table 16.180: Strimvelis®: Sales Forecast for ADA-SCID, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.181: Strimvelis®: Sales Forecast for ADA-SCID, Base Scenario, Till 2030 (USD Million)
  • Table 16.182: Strimvelis®: Sales Forecast for ADA-SCID, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.183: Strimvelis®: Sales Forecast by Geography for ADA-SCID, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.184: Strimvelis®: Sales Forecast by Geography for ADA-SCID, Base Scenario, Till 2030 (USD Million)
  • Table 16.185: Strimvelis®: Sales Forecast by Geography for ADA-SCID, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.186: OTL-200: Sales Forecast for Metachromatic Leukodystrophy, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.187: OTL-200: Sales Forecast for Metachromatic Leukodystrophy, Base Scenario, Till 2030 (USD Million)
  • Table 16.188: OTL-200: Sales Forecast for Metachromatic Leukodystrophy, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.189: OTL-200: Sales Forecast by Geography for Metachromatic Leukodystrophy, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.190: OTL-200: Sales Forecast by Geography for Metachromatic Leukodystrophy, Base Scenario, Till 2030 (USD Million)
  • Table 16.191: OTL-200: Sales Forecast by Geography for Metachromatic Leukodystrophy, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.192: Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast for Type 1 Diabetes, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.193: Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast for Type 1 Diabetes, Base Scenario, Till 2030 (USD Million)
  • Table 16.194: Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast for Type 1 Diabetes, Opportunistic Scenario, Till 2030 (USD Million)
  • Table 16.195: Unnamed Stem Cell Therapy by Global Cell Med : Sales Forecast by Geography for Type 1 Diabetes, Conservative Scenario, Till 2030 (USD Million)
  • Table 16.196: Unnamed Stem Cell Therapy by Global Cell Med : Sales Forecast by Geography for Type 1 Diabetes, Base Scenario, Till 2030 (USD Million)
  • Table 16.197: Unnamed Stem Cell Therapy by Global Cell Med : Sales Forecast by Geography for Type 1 Diabetes, Opportunistic Scenario, Till 2030 (USD Million)

Listed Companies:

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  • 1. 3P Biopharmaceuticals
  • 2. 4BIO Capital
  • 3. 6 Dimensions Capital
  • 4. Advanced Stem Cell Rx
  • 5. Agent Capital
  • 6. Aldagen
  • 7. Altaco XXI
  • 8. Andalusian Initiative for Advanced Therapies
  • 9. Ankara University
  • 10. apceth Biopharma
  • 11. ARCH Venture Partners
  • 12. ArrowMark Partners
  • 13. ASAP Ventures
  • 14. Aspire Capital
  • 15. Asset Management Partners
  • 16. Assistance Publique - HÔpitaux de Paris
  • 17. Athersys
  • 18. Baillie Gifford
  • 19. Bain Capital Life Sciences
  • 20. Barts Health NHS Trust
  • 21. Batipart
  • 22. Beyond Type 1
  • 23. BioCardia
  • 24. BioLamina
  • 25. BioRestorative Therapies
  • 26. Boston Children's Hospital
  • 27. Boyalife Group
  • 28. Bpifrance
  • 29. Broadfin Capital
  • 30. BTIG
  • 31. Caladrius Biosciences
  • 32. California Institute for Regenerative Medicine
  • 33. Capricor Therapeutics
  • 34. CardioCell
  • 35. Celgene
  • 36. Celixir
  • 37. CellPraxis Bioengeneering
  • 38. CellProthera
  • 39. Celyad
  • 40. Center for Cellular Technologies
  • 41. Center for iPS Cell Research and Application
  • 42. Cesca Therapeutics
  • 43. Cha Bio&Diostech
  • 44. Chinese Academy of Sciences
  • 45. Cipla
  • 46. Cognate BioServices
  • 47. Colorado Center for Reproductive Medicine
  • 48. Columbia University
  • 49. Compass Biomedical
  • 50. CORD:USE
  • 51. CORESTEM
  • 52. Cormorant Asset Management
  • 53. Cowen Healthcare Investments
  • 54. CRISPR Therapeutics
  • 55. CureDuchenne Ventures
  • 56. Cytopeutics
  • 57. Cytori Therapeutics
  • 58. Dai Nippon Printing
  • 59. Daiichi Sankyo
  • 60. Deerfield Management
  • 61. Defymed
  • 62. Driehaus Capital Management
  • 63. DUKE National University Singapore Medical School
  • 64. East Capital
  • 65. East West Capital Partners
  • 66. Eli Lilly
  • 67. Evotec
  • 68. Federal Research And Clinical Center
  • 69. Flagship Pioneering
  • 70. Foresite Capital
  • 71. F-Prime Capital
  • 72. Fuzhou General Hospital
  • 73. General American Capital Partners
  • 74. Ghost Tree Capital
  • 75. GlaxoSmithKline
  • 76. Global Cell Med
  • 77. Gore
  • 78. Great Ormond Street Hospital
  • 79. Green Cross Health
  • 80. GRI Fund
  • 81. H.C. Wainwright
  • 82. H2M Capital
  • 83. Harvard Stem Cell Institute
  • 84. Healios
  • 85. Hercules Capital
  • 86. Hospital La Paz Institute for Health Research
  • 87. Hunton & Williams
  • 88. Imperial College London
  • 89. Innovative Cellular Therapeutics
  • 90. Innovative Medical Management
  • 91. Invetech
  • 92. IRCCS San Raffaele
  • 93. Israel Innovation Authority
  • 94. Janssen Biotech
  • 95. JDRF
  • 96. Johann Wolfgang Goethe University Hospital
  • 97. Johnson & Johnson
  • 98. Johnson Trust
  • 99. Juda Capital
  • 100. Kadimastem
  • 101. Kempen
  • 102. Ladenburg Thalmann
  • 103. Leerink Partners
  • 104. Lifecell
  • 105. Lincoln Park Capital
  • 106. Lorem Vascular
  • 107. LSK Partners
  • 108. Ludwig Boltzmann Institute
  • 109. M D Anderson Cancer Center
  • 110. Magna Equities
  • 111. Maryland Stem Cell Research Fund
  • 112. McEwen Stem Cell Institute
  • 113. Medical University of Silesia
  • 114. Medical University of South Carolina
  • 115. Medison Ventures
  • 116. Medisun International
  • 117. MedStar Heart & Vascular Institute
  • 118. Medtronic
  • 119. Medytox
  • 120. Mesoblast
  • 121. MidCap Financial
  • 122. Miltenyi Biotec
  • 123. Minovia Therapeutics
  • 124. Moraga Biotechnology
  • 125. MPM Capital
  • 126. Nanjing Drum Tower Hospital
  • 127. National Cardiovascular Center Harapan Kita Hospital
  • 128. National Heart Centre Singapore
  • 129. National Heart, Lung, and Blood Institute
  • 130. National Institute of Diabetes and Digestive and Kidney Diseases
  • 131. National Institutes of Health
  • 132. National University of Ireland
  • 133. Nile Therapeutics
  • 134. Novartis
  • 135. Novo Nordisk
  • 136. Nuo Therapeutics
  • 137. Okayama University
  • 138. Orchard Therapeutics
  • 139. ORI Healthcare Fund
  • 140. Osaka University
  • 141. Oxford BioMedica
  • 142. Oxford Finance
  • 143. Pavilion Capital
  • 144. Peking University Aerospace Centre Hospital
  • 145. Perceptive Advisors
  • 146. PharmaCell
  • 147. Pharmicell
  • 148. Piper Jaffray
  • 149. Pontifical Catholic University of Paraná
  • 150. Postgraduate Institute of Medical Education and Research
  • 151. Progenitor Cell Therapy
  • 152. Queen Mary University of London
  • 153. RA Capital Management
  • 154. ReNeuron
  • 155. RHEACELL
  • 156. Rigshospitalet
  • 157. Royal Brompton and Harefield NHS Foundation Trust
  • 158. Royan Institute
  • 159. RTW Investments
  • 160. Sabby Capital
  • 161. Sakakibara Heart Institute
  • 162. Sanderling Ventures
  • 163. Sanford Health
  • 164. Sanofi
  • 165. SC&H Capital
  • 166. Sclnow Biotechnology
  • 167. Semma Therapeutics
  • 168. Seraxis
  • 169. Shanghai 10th People's Hospital
  • 170. Shanghai Biotechnology
  • 171. Shavit Capital
  • 172. Shire
  • 173. Sigilon Therapeutics
  • 174. Silicon Valley Bank
  • 175. Sinopharm Capital
  • 176. Sosei
  • 177. South China Research Center for Stem Cell and Regenerative Medicine
  • 178. Sphera Global Health Care
  • 179. SPS Cardio
  • 180. Stem Cell and Regenerative Medicine Institute
  • 181. Stem cell unit, Van Hanh General Hospital
  • 182. Stem Cells Arabia
  • 183. Stempeutics Research
  • 184. SymbioCellTech
  • 185. Takeda Pharmaceutical
  • 186. Tasly Pharmaceutical
  • 187. Tel Aviv University
  • 188. Temasek
  • 189. Terumo BCT
  • 190. The Champ Foundation
  • 191. Thomson Medical Centre
  • 192. Tianhe Stem Cell Biotechnologies
  • 193. Tiger X Medical
  • 194. TMC Life Sciences
  • 195. Topstone Research
  • 196. Toulouse University Hospital
  • 197. TPG
  • 198. U.S. Stem Cell
  • 199. University Health Network
  • 200. University Hospital, Clermont-Ferrand
  • 201. University Hospital, Ostrava
  • 202. University Medical Center, Utrecht
  • 203. University Medical Centre Ljubljana
  • 204. University of Bristol
  • 205. University of California
  • 206. University of Florence
  • 207. University of Glasgow
  • 208. University of Jordan
  • 209. University of Kentucky
  • 210. University of Manchester
  • 211. University of Miami
  • 212. University of Minnesota - Clinical and Translational Science Institute
  • 213. University of Pennsylvania
  • 214. University of Texas Health Science Center, Houston
  • 215. University of Ulm
  • 216. University of Utah
  • 217. Venrock
  • 218. Vericel
  • 219. ViaCyte
  • 220. Vinmec Research Institute of Stem Cell and Gene Technology
  • 221. Viscofan BioEngineering
  • 222. Wood Capital
  • 223. Wu Capital
  • 224. Xcelthera
  • 225. Zheshang Venture Capital
Back to Top